The effect of administration of metformin on lipid profile changes andinsulin resistance in patients with polycystic ovary syndrome
Abstract
Objective: Polycystic ovary syndrome (PCOS) is one of the most common metabolism and endocrine disorders among women. The aim of the present study was to evaluate the effects of metformin on lipid profile changes, insulin resistance, body mass index (BMI), Ovulation and pregnancy rates in patients affected by PCO syndrome. Materials and Methods: In this randomized controlled study, 200 women aged 20-35 years with PCOS were selected. Diagnostic criteria were based on the diagnostic criteria of PCO syndrome in Noterdam meeting in 2003. Samples of fasting peripheral blood were taken from all patients to test cholesterol, LDL, HDL, TG, FBS and Insulin before treatment. Patients were then divided randomly into two groups. In case group (n=100), metformin was prescribed three times a day (1500 mg daily) and in control group (n=100), placebo was administered in the same way. After three months, sample of blood was taken again in order to test the variance of the above mentioned parameters to compare with these amounts before test. Also, BMI was compared before and after treatment in both groups. Results: BMI was 28.81±3.18 and 29.49 ± 4.7 Kg/m2 before treatment in case and control groups respectively. This ratio changed after treatment to 28.45 ± 2.8 and 29.29 ± 4.8 Kg/m2 in case and control groups respectively (P-value>0.05). FSH/insulin ratio was 4.67±0.9 and 5.03±1.3 in case and control group respectively, while it changed after treatment to 6.07 ± 1.4 and 5.05 ±1.3 and this…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 200 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.